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ABSTRACT 
Numerous studies have been published concerning both the 
various diseases which cause dysfunctional ovulation, and the 
pregnancy induction success rates of the medical and surgical 
therapy for these disorders. However, little work has been done 
to determine the necessity for ovulation induction in subsequent 
pregnancies in women with these syndromes. In this study I 
analyzed 103 patients with dysfunctional ovulation who had 
conceived once with ovulation inducing agents. Of these, 36 
patients were interested in achieving another pregnancy. 
Twenty-five of these patients (69%) conceived spontaneously the 
second time (p<0.1). Intermittent ovulation or psychogenic 
factors are hypothesized to explain this significant rate of 
spontaneous pregnancy. 
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1. INTRODUCTION 
One of every five American couples are infertile. Of 
these, between 13 and 50% have ovulatory factors contributing to 
their infertility. “ Numerous studies have been published 
concerning both the various diseases causing dysfunctional 
ovulation, and the medical and surgical therapy for these 
disorders. These studies have included successs rates in terms of 
both ovulation induction and pregnancy for each of these treat¬ 
ments. However, little work has been done to determine the 
necessity of ovulation induction in subsequent pregnancies. In 
light of the expense and often undesirable side effects of the 
current pharmacologic therapy for infertility, it is important to 
be able to advise the infertile couple as to what the probability 
would be of spontaneously conceiving in future pregnancies, given 
a history of a particular ovulatory dysfunction. 
(1) 

2. BACKGROUND 
DISORDERS CAUSING OVULATORY FAILURE 
There are many disorders which cause primary and secondary 
amenorrhea. These include primary ovarian failure, primary hypo¬ 
thalamic failure, primary pituitary failure, hyperprolactinemia, 
polycystic ovary disease, luteal deficiency, and hypothalamic 
feedback disorders.^ In the following sections, I will address 
those disorders which are most frequently seen in an infertility 
practice and are most amenable to treatment. These include poly¬ 
cystic ovary disease, short luteal phase, hyperprolactinemia, and 
hypothalamic dysfunction. 
POLYCYSTIC OVARY DISEASE 
In 1935, Drs. Irving Stein and Michael Leventhal described 
a syndrome consisting of amenorrhea, infertility, and hirsutism 
o 
associated with bilateral polycystic ovaries. They employed 
pneumoroentgenography to diagnose the abnormal ovaries and init¬ 
ially used intramuscular injections of estrogenic preparations 
for treatment, with little success. They reported seven cases of 
patients who became normoovulatory after bilateral ovarian wedge 
resection, a procedure which entailed removing a portion of the 
(2) 

cystic cortex of the ovaries. Their hypothesis for the etiology 
of amenorrhea and sterility in patients with this syndrome was 
based on mechanical considerations; they reasoned that the crowd¬ 
ed abnormal cysts prevented normal graafian follicles from migrat 
ing to the surface of the ovary preparatory to ovulation. 
Since the original work by Stein and Leventhal, there has 
been much work done on the etiology, diagnosis, and treatment of 
this disease, which is thought by many to encompass several dis¬ 
crete syndromes. This is illustrated by the work of Goldzieher 
and Axelrod who analyzed 1097 cases from 187 reports of surgical- 
9 
ly documented polycystic ovaries. The incidence of clinical 
symptoms varied widely amongst the reports, however, the mean 
incidence of the various symptoms were as follows: infertility 
74%, hirsutism 69%, amenorrhea 51%, obesity 41%, functional bleed 
ing 29%, dysmenorrhea 23%, corpus luteum at operation 22%, viril¬ 
ization 21%, biphasic basal temperature 15%, cyclic menses 12%. 
The authors conclude from these statistics that Stein and Leven¬ 
thal described only a small fraction of the spectrum of polycys¬ 
tic ovary disease (PCOD). This has presented a problem in terms 
of clinical diagnosis, therefore, endocrinological studies have 
been turned to as an aid in diagnosis. Yen et_ al_ showed abnorm¬ 
al gonadotropin secretion in patients with documented polycystic 
ovaries.^ The serum luteinizing hormone (LH) secretory 
(3) 

pattern consisted of erratic fluctuations with a high baseline, 
instead of the cyclical pulsatile secretion found in normal 
women. The mean serum follicle stimulating hormone (FSH) concen¬ 
trations were lower than normal during early follicular phase and 
comparable to normal during late follicular phase. DeVane et al 
measured hormone concentrations in 19 PCOD patients and 10 normal 
women.11 They found significantly higher concentrations of es¬ 
trone, testosterone, androstenedione, and LH in the serum of the 
PCOD patients compared to normals. FSH and estradiol levels, how¬ 
ever, were comparable in the two groups. 
Since the initial report by Stein and Leventhal, there has 
been much speculation as to the pathogenesis of the polycystic 
ovary syndrome. Their mechanical barrier theory, mentioned pre¬ 
viously, has been discredited as have the ideas of Miklowski and 
McCosker who postulated autoimmunity to gonadotropins as the 
12 
cause of polycystic ovary formation and Reynolds who believed 
that increased hydrostatic pressure in the ovarian vasculature 
led to the transudation of fluid into the follicles, causing cyst 
13 formation. These theories have been discarded in the face of 
increasing knowledge of the neuroendocrine interrelationship 
between the hypothalamus, pituitary and ovaries. 
A recent comprehensive consideration of the endocrinology 
of the menstrual cycle includes a hypothesis of the cause of 
14 polycystic ovary disease as follows. Aromatization of thecal 
(4) 

cell androgens to estrogens early in the follicular phase occurs 
in the granulosa cells. A positive feedback mechanism exists 
allowing FSH and estrogen together to raise the concentration of 
FSH receptor. Androgen receptors are also present in the cytoplasm 
of the granulosa cells. At low androgen concentrations, the 
androgens enhance their own aromatization to estrogens. At higher 
concentrations, however, androstenedione is converted to more 
potent androgens, rather than to estrogens. These androgens, in 
turn, cannot be converted to estrogens. Simultaneously, the 
decrease in local estrogens impairs FSH receptor formation so that 
FSH induction of aromatization is diminished, further decreasing 
ovarian estrogen production. Follicles, therefore, become atretic 
instead of developing naturally. 
As for the cause of elevated androgen levels in these pat¬ 
ients, recent work has demonstrated that in patients with PCOD, 
15 there is enhanced bioactivity of LH. Since LH induces andro¬ 
gen synthesis by the theca cells, this may partially explain the 
elevated androgen levels in these patients. It has also been 
shown that there is an increased sensitivity to luteinizing hor¬ 
mone releasing hormone (LHRH) in PCOD patients which leads to the 
1 C 
increased release of LH found in this syndrome. This may re¬ 
sult from chronically elevated circulating estrogen levels caused 
(5) 

by peripheral conversion of androstenedione to estrogen in the 
adipose tissue of these frequently obese patieents. By direct 
action on the pituitary, these elevated estrogens can augment 
pituitary sensitivity to LHRH."''7 Another explanation for the 
state of androgen excess is that PCOD patients have a decrease in 
testosterone-binding globulin (TeBG). In normal women 96% of cir¬ 
culating testosterone is bound to TeBG, while in PCOD women only 
92% of the hormone is bound. Thus, these patients have not only 
higher serum testosterone levels, but also a higher percentage of 
18 
the hormone is available for biological activity. 
Treatment of PCOD 
Initial reports of successful management of PCOD in terms of 
promoting cyclic ovulation and fertility were based on surgical 
treatment. Stein and Leventhal reported a 100% success rate in 
inducing ovulation in their first series of patients with a 30% 
g 
pregnancy rate. In a later series reported by Stein and Cohen 
90% of the patients became ovulatory and 60% achieved pregnan- 
19 
cy. In the review of 1097 cases by Goldzieher and Axelrod, 
the mean frequency of restoration of regular cycles was 80% and 
g 
of pregnancy was 63%, tabulated from 187 reports. Judd et al 
showed that ovarian wedge resection resulted in a significant 
transient reduction of ovarian androstenedione and a persistent 
20 
reduction of testosterone secretion. Katz et al reported 
(6) 

that postoperatively the LH:FSH ratio decreased significantly and 
cyclic gonadotropin activity was noted during the first week. Dur¬ 
ing the second postoperative week there was an estradiol surge 
followed by LH and FSH peaks. This led to ovulation by the end 
of the first postoperative month. They also noted an intraopera- 
21 tive fall in plasma estradiol concentration. This may lead 
to facilitation of FSH secretion which may cause follicular de- 
12 
velopment and consequent ovulation. 
With the development of hormonal therapy for dysfunctional 
ovulation, ovarian wedge resection was relegated to a treatment 
of last resort. This was especially true in light of the fact 
that reports of failure due to postoperative complications began 
to appear in the literaure. For example, Toaff et al_ reported on 
22 
seven cases of wedge resection failure. At laparoscopy, all 
patients exhibited extensive periovarian and peritubal adhesions. 
In addition, they noted one case of bilateral and two cases of 
unilateral ovarian atrophy. 
The unexpected action of clomiphene citrate (Clomid) in 
promoting ovulation in anovulatory women was discovered in the 
early 1960's while testing the compound for contraceptive effect- 
23 24 iveness. * The first report of its efficacy for treating 
PCOD patients is found in a series of four patients studied by 
25 Kistner and Smith. All four of their patients became 
(7) 

ovulatory as a result of this therapy, three of whom achieved 
pregnancy. Later it was determined that Clomid acts as a compe¬ 
titive inhibitor of estrogen binding to pituitary receptors, thus 
9 Ft 
interrupting negative feedback on FSH secretion. Reports 
of success rates for Clomid in inducing ovulation in PCOD pat¬ 
ients range from 60 to 90% with an approximately 20% pregnancy 
24 27 29 
rate. * * By causing an increase in FSH secretion, Clomid 
induces follicular maturation and a pre-ovulatory FSH and LH peak 
occurs three to nine days after cessation of therapy leading to 
, . . 30 
ovul ation. 
In patients who do not respond to Clomid, human menopaus¬ 
al gonadotropins (HMG) is the next therapy of choice. As early 
as the 1940's animal experiments showed successful induction of 
ovulation using homologous pituitary extracts. Van Wagenen and 
Simpson used FSH from rhesus monkey pituitaries mixed with human 
gonadotropin to induce ovulation in both mature and immature rhe- 
31 
sus monkeys. In an early test on 40 women using a partially 
purified human pituitary preparation of FSH, Gemzell et aj_ found 
polycystic enlargement of the ovaries and highly elevated urinary 
32 
estrogen levels. In the PCOD women tested, ovulation was in¬ 
duced within three days of treatment. 
It is interesting to note one study of FSH administration 
in PCOD patients. Keetel trt al_ observed marked ovarian enlarge¬ 
ment after therapy as opposed to controls who showed no change in 
(8) 

33 
ovarian size. They concluded from this that FSH administra¬ 
tion, followed by bimanual pelvic examination, was a good clini¬ 
cal test for the presence of polycystic ovaries. 
The dose of human gonadotropins has been standardized re¬ 
cently; the most commonly used preparation in Pergonal, an ampule 
of which consists of 75 IU FSH and 75 IU of LH purified from the 
urine of postmenopausal women. Human chorionic gonadotropin 
(HCG) has biological properties which are similar to LH. It is 
obtained from the urine of pregnant women and is used in conjunc¬ 
tion with Pergonal to induce ovulation of the mature follicle. 
Van de Wiele et al_ reported a series of 35 patients with 
dysfunctional ovulation treated with the combined regimen of 
34 Pergonal and HCG. Ten of these patients had PCOD, three were 
status post failed wedge resections. All of these patients ovu¬ 
lated while receiving this therapy. Thompson and Hansen publish¬ 
ed a computer tabulation of results of Pergonal therapy of 1,286 
35 patients from 100 investigators. Of these patients, 212 had 
proven or probable polycystic ovary disease. Sixty-two percent 
of the cycles, representing 76% of patients ovulated with various 
combinations of menotropins and/or clomiphene, with a pregnancy 
rate of only 26%. Of these pregnancies, 39% resulted in abortion, 
and 17% yielded multiple gestations. There was a 1.1% incidence 
of hyperstimulation syndrome. This was comparable with the inci¬ 
dence of hyperstimulation in other patient categories, which does 
(9) 

not support earlier reports that PCOD patients are more prone to 
hyperstimulation than other patients with dysfunctional ovula¬ 
tion. A more recent report of combination HMG-HCG treatment for 
PCOD yielded higher ovulation, pregnancy, and complication 
Of 
rates. Of 41 women treated, there was a 97.4% rate of ovula¬ 
tory cycles (number of patients represented by this unreported), 
a 65.9% pregnancy rate, a 36.3% multiple gestation rate, a 24.1% 
abortion rate, and an 11.7% rate of ovarian hyperstimulation. It 
was conduced that while the pregnancy rate was the same as in 
women with anovulation for other reasons, the incidence of spon¬ 
taneous abortion and hyperstimulation was higher. 
In light of the high incidence of undesirable complica¬ 
tions of this therapy, recent trials have sought to modify the 
HMG-HCG treatment in an attempt to prevent these side effects. 
Kamrava et al_ tried using low-dose FSH alone to induce ovulation 
37 in two PCOD patients. Both patients became pregnant, with 
one aborting at 10 weeks. The authors reasoned that with the al¬ 
ready high LH levels in PCOD patients, the addition of exogenous 
LH might be the causal factor in hyperstimulation and multiple 
pregnancy. The efficacy of FSH alone in reducing complications 
while inducing ovulation requires further study. 
Corticosteroids and oral contraceptives are other medical 
treatments for PCOD. Since they do not enhance fertility, but 
are sometimes useful for the relief from other symptoms of PCOD, 
they will not be considered further here. 
(10) 

II. INADEQUATE.LUTEAL PHASE 
The corpus luteum is the main source of luteal phase pro- 
14 gesterone. McNatty delineated three conditions which must be 
fulfilled in order for a follicle to become a functioning corpus 
38 luteum. These include: (1) sufficient granulosa cells in the 
follicle prior to ovulation (2) the granulosa cells must be able 
to produce enough progesterone (3) both the granulosa and theca 
cells must have sufficient LH receptors to be responsive to that 
hormone. The importance of the evaluation of the luteal phase in 
39 infertility was first described by Jones in 1949. In her 
population of infertility patients in whom anatomic factors had 
been ruled out, 14% of the cycles studied exhibited inadequate 
luteal phase on the basis of basal body temperature charts, while 
50% showed luteal defects when endometrial biopsies were used for 
diagnosis. Jones advocated elimination of excessive alcohol in¬ 
take and smoking, and adequate rest and dietary protein in addi¬ 
tion to 60 milligrams of pregneninolone daily as therapy for this 
disorder. 
Later reports have given a range of 3 to 10% incidence of 
40 41 
short luteal phase in infertile women. ’ Since Jones' ini¬ 
tial publication, there have been many attempts to explain the 
pathophysiology of this entity and also much controversy over the 
optimal means of diagnosis. Strott et al noted that after the 
(11) 

midcycle LH surge in these patients, lower than normal amounts of 
progesterone were secreted leading to endometrial sloughing only 
42 
six to eight days later. They hypothesized that the short 
luteal phase was due to deficient preovulatory FSH levels leading 
to inadequate luteinization. DiZerega and Hodgen point out that 
numbers of progesterone and estradiol receptors in the endome¬ 
trium vary during the menstrual cycle depending on the circulat- 
43 ing steroid levels. They cite animal studies which indicate 
that for implantation to occur, a certain level of steroid recep¬ 
tors must be present in the endometrium. This could explain why 
a deficiency in progesterone would not permit nidation. In addi¬ 
tion, there is evidence that probably for the same reason, defec¬ 
tive corpora lutea are unable to respond to HCG, which normally 
43 
allows maternal recognition of pregnancy. 
In addition to the importance of the accumulation of suffi 
cient LH receptors during the follicular phase to ensure luteini¬ 
zation and normal functioning of the corpus luteum, it is neces¬ 
sary that low-density-lipoproteins (LDL) be available as a source 
14 
of cholesterol for progesterone synthesis. After ovulation, 
a vascularization of the granulosa occurs. This allows LDL to 
reach the luteinized granulosa to be used in progesterone synthe¬ 
sis. Another corpus luteum function is continued tonic LH secre¬ 
tion after the LH surge. 
(12) 

It is apparent then, that both adequate fol1iculogenesis 
and maintenance of the corpus luteum after ovulation are neces¬ 
sary for normal endometrial implantation to occur. 
There have been various methods proposed for diagnosing 
this condition. In Jones' original article, she advocated premen 
39 
strual endometrial biopsy as the diagnostic test of choice. 
Almost 30 years later, she still recommended this method of diag- 
40 
nosis. If the biopsy is out of phase by two or more days, 
another biopsy should be obtained in a later cycle to confirm the 
findings. The biopsy is dated according to the histologic criter 
44 ia of Noyes et al_. Soules et al^ agree that the method of 
choice for diagnosis of luteal phase defects is endometrial 
biopsy and advocates using the menstrual period following the 
45 biopsy as the reference point. Other studies also favor endo- 
46 47 
metrial biopsies as a diagnostic technique. * 
Serum progesterone determinations have also been used for 
diagnosis. Israel and colleagues determined that progresterone 
values of 3 ng/ml or greater obtained between 11 and four days 
prior to the onset of menstruation could be used as presumptive 
48 
evidence of ovulation. The advantage of this method over 
endometrial biopsy is the ease and minimal discomfort of perform¬ 
ing a venipuncture as opposed to the pain involved with a biopsy. 
Other investigators also believed that a single, well-timed serum 
(13) 

progesterone assay is more accurate than a single endometrial 
49 biopsy for evaluation of luteal function. Abraham et al, 
however, challenged the accuracy of a single progesteone determina¬ 
tion and recommended a more complicated scheme for determining 
50 
adequate luteal function based on three progesterone measurements. 
They calculated that from 4 to 11 days before menstruation, three 
separate progesterone determinations taken from the same cycle would 
total 15 ng/ml or greater if the cycle was normal. If the sum of the 
three progesterone levels equaled less than this amount, then this 
indicated abnormal luteal function. The disadvantage of this technique 
is its relative inconvenience in that three venipunctures at different 
times during one week are required. 
A third method of diagnosing luteal problems is using basal body 
temperature graphs. Jones criticized this approach, stating that some 
women have a poor thermogenic response to progesterone which would give 
40 
a false positive indication of a luteal defect. In addition she 
notes the usual problems of temperature curves due to patient incon¬ 
sistencies in methodology. 
Today most clinicians employ the endometrial biopsy to diagnose 
abnormal cycles. It should be performed two days before the expected 
onset of menses because at that time the endometrium reflects 
stimulation by progesterone for almost the entire life span of the 
corpus luteum.^1 
(14) 

Treatment of Inadequate Luteal Phase 
There have been many pharmacological treatments described 
for short luteal phase. In light of the low serum progesterone 
levels present in this condition, progesterone replacement is 
often efficacious. A 50 to 70% pregnancy rate has been reported 
52 54 
with progesterone therapy. * Moszkowski and associates re¬ 
ported successful correction of the luteal defect using various 
forms of progesterone replacement including oral, sublingual, in- 
55 tramuscular, and suppository treatment. These results were 
56 later confirmed. Of these routes of administration, it has 
been shown that synthetic oral progestagens may suppress endo- 
57 genous production of progesterone by the corpus luteum. 
Therefore, this form of progesterone replacement should not be 
employed to treat women with short luteal phase. 
As mentioned before, levels of serum FSH indirectly 
influence the status of the corpus luteum by its effect on the de¬ 
veloping follicle, while LH is necessary to prolong luteal func¬ 
tion. For this reason clomiphene, an anti-estrogen, has been 
recommended to treat short luteal phase since it causes an increase 
fin 
in serum gonadotropins. " Echt et al_ reported a 21% pregnancy 
C 1 
rate using this drug. Another series of 26 patients only had an 
CO 
11% pregnancy rate. The authors of this report went on to treat 
those patients who had failed Clomid therapy with progesterone 
(15) 

suppositories. Many of these patients successfully conceived. 
Therefore, they concluded that Clomid is not the drug of choice 
for treating short luteal phase. Another argument against the 
use of Clomid for short luteal phase is that Clomid itself has 
63 64 been shown by some to cause luteal phase defects 5 This 
controversy has not been resolved. 
In order to directly increase levels of circulating gonado¬ 
tropins, human menopausal gonadotropin may be administered. This 
treatment for inadequate luteal phase was first described by Shapi- 
65 
ro in 1972. He reported on a patient who did not respond to 
combination Clomid and HCG therapy, but did become pregnant using 
Pergonal and HCG. Jayle and Palmer quoted two reports from the 
French literature where HMG and HCG, and HMG alone were used to 
CO 
treat luteal insufficiency. In the former, by Palmer and 
Kamoun, 32% of the patients became pregnant. Sixty-three of the 
births were normal; five percent of the pregnancies were ectopic, 
and 29% resulted in spontaneous abortions. Using the HMG alone 
Jayle et al_ achieved a 50% pregnancy rate, using higher doses of 
HMG than Palmer and Kamoun. In a recent report patients who had 
failed high dose Clomid or Clomid plus HCG were treated with se- 
fifi 
quential HMG and HCG. Of those patients with poor corpus 
» 
luteum function, 50% became pregnant with this treatment. Of 
these pregnancies, 13% ended in spontaneous abortions, and five 
(16) 

percent resulted in multiple gestation. Interestingly, this 
group presented evidence that while the monthly probability of 
pregnancy was only nine percent for the first three months of 
treatment, it increased to 90% for the second three months of 
treatment. This may indicate that the ovaries have to be primed 
66 for a few months before they can respond. 
Another therapy for this type of ovulatory dysfunction 
which is sometimes effective is bromocriptine. The indications 
for use of this medication will be discussed in the following 
section. 
III. HYPERPROLACTINEMIA 
The amenorrhea-galactorrhea syndrome was described as 
early as 2,000 years ago by Hippocrates: "If a woman who is not 
with child, nor has brought forth, have milk, her menses are ob¬ 
structed."^ However, it was not until recent years, with the 
advent of hormonal assay techniques, that this syndrome has begun 
to be understood. In 1932 there was two case reports in The 
Lancet describing spontaneous lactation associated with an enlarged 
68 
sella turcica. The authors related evidence which indicated 
that the anterior pituitary influences mammary activity and 
postulated the existence of a "mammary hormone". Twenty years 
(17) 

later Forbes et al_ presented 15 women with amenorrhea and galac- 
69 torrhea associated with low urinary FSH. On skull x-ray, 
seven had evidence of a pituitary tumor; three of these had docu¬ 
mented chromophobe adenomas on biopsy. The authors proposed that 
all of the patients had overproduction of prolactin by the pitui¬ 
tary, whether or not a tumor was present. Similar cases were re¬ 
ported by £rgonz and Del Castillo.^ over the years there was 
much controversy concerning whether or not prolactin existed as a 
unique hormone. Human growth hormone itself possesses strong in¬ 
trinsic lactogenic properties, and, therefore, detection of the 
small amounts of prolactin present in human pituitary extracts 
was difficult.^1 
A breakthrough came in 1970 when a sensitive bioassay for 
72 prolactin was published. This assay was based on the ability 
of prolactin to cause differentiation and milk secretion of mouse 
breast tissue in vitro. By means of this assay, prolactin was 
for the first time shown to be immunologically distinct from 
growth hormone. Using this method, Forsyth et al_ detected prolac¬ 
tin in the plasma of patients with galactorrhea, both with and 
73 
without pituitary tumors. Shortly thereafter, a radioimmuno- 
74 
assay was developed for prolactin. This radioimmunoassay 
131 
used I labelled monkey prolactin and antibodies to monkey or 
human prolactin. Radioimmunoassay is today the definitive 
method for measurement of prolactin in human serum. 
(18) 

Treatment of Hyperprolactinemia 
Radiation or surgical treatment of pituitary tumors was 
usually successful in curing the amenorrhea-galactorrhea syndrome 
in patients where tumors were found to be present. However, the 
treatment of "idiopathic" galactorrhea up until this time was 
based on oral contraceptives and estrogen, although it was recog- 
75 
nized that estrogen could stimulate prolactin secretion. In 
fact, it had been noted that exogenous estrogen could itself 
76 
cause galactorrhea. Selected cases of amenorrhea-galactor¬ 
rhea responded to sequential treatment with clomiphene citrate and 
HCG'7'7, but this was not uniformly successful. The first defini¬ 
tive treatment for this syndrome was L-dopa, which was routinely 
used for patients with Parkinson's disease. On the basis of the 
fact that increased hypothalamic concentrations of dopamine were 
78 
shown to inhibit prolactin secretion in animals, Turkington 
tried using L-dopa, the precursor of dopamine, to treat amenorrhea- 
79 galactorrheic patients. Forty percent of the patients became 
normoprolactinemic with L-dopa therapy. An additional 35% of the 
patients became clinically asymptomatic, although their prolactin 
levels did not completely normalize with treatment. Similarly 
on 
promising results were also obtained by Zarate et al_. Simul¬ 
taneously as this reseach on L-dopa was proceeding, a new drug 
(19) 

also was showing promise of effectively treating this disorder. 
In 1971 Lutterbeck et al_ descri bed successful treatment of galac- 
81 
torrhea using the ergot alkaloid, 2-Br-alpha-ergocryptine, 
which had previously been shown to interfere with pituitary pro¬ 
lactin production in animals. Other reports confirmed the effect 
iveness of this drug in resolving galactorrhea and inducing ovula 
82 84 tory cycles. * Bromocriptine is superior to L-dopa for 
treating this condition because frequent administration of L-dopa 
is necessary due to its short duration of action. 
In order to understand the mechanism of action of bromo¬ 
criptine (Parlodel), it is necessary to understand the pathophys¬ 
iology of the amenorrhea-galactorrhea syndrome. Although still 
not completely elucidated, there is data to support hypothalamic, 
pituitary, and ovarian mechanisms. Prolactin differs from other 
pituitary hormones in that it is tonically controlled by an in¬ 
hibitory, rather than stimulatory, factor from the hypothalamus. 
Dopamine, the precursor to norepinephrine, inhibits prolactin re¬ 
lease from the pituitary. It is possible, therefore, that prolac 
tin may be the so-called prolactin inhibitory factor (PIF), or at 
85 least be a part of it. In addition, dopamine inhibits GnRH 
release. The following chain of events was proposed by Wutke et 
86 
al. Hyperprolactinemia positively feeds back on hypothalamic 
dopamine causing increased inhibition of GnRH release. The 
(20) 

dopamine receptor may gradually become desensitized due to the 
continuously high dopamine turnover. Consequently, dopamine may 
become less and less effective in inhibiting GnRH release leading 
to acyclicity of LH and FSH release. This leads to anovulation 
12 
and amenorrhea. Bromocriptine, as a dopamine agonist, would 
then be effective in restoring LH levels to normal leading to 
cyclic ovulatory cycles. The etiology of pituitary adenoma forma¬ 
tion may be due to dysfunction in dopamine sensitivity to 
87 prolactin feedback. This would lead to hypersecretion of pro¬ 
lactin by the pituitary, eventually causing hyperplasia of the 
pituitary lactotrophs, or prolactin secreting cells. 
At the ovarian level, FSH induces specific prolactin recep- 
14 tors on granulosa cells in the rat. Prolactin is always pre¬ 
sent in follicular fluid and it causes interruption of FSH induc- 
14 
ed aromatization of androgen to estrogen in that animal. This 
evidence suggests that hyperprolactinemic women may be anovula¬ 
tory on the ba-sis of events at the ovarian level. 
It has been shown that hyperprolactinemia can cause luteal 
phase defects. This has been illustrated in the case of amenor- 
rheic lactating mothers where hyperprolactinemia causes luteal 
oo 
insufficiency and subsequent impaired progesterone secretion. 
If hyperprolactinemia disrupts the cyclic patterns of LH and FSH 
release, this could explain its effects on the corpus luteum. As 
(21) 

mentioned in the previous section, both normal fol1iculogenesis 
under control by FSH, and normal luteal maintenance by LH are 
necessary for normal luteal lifespan. Corenblum and colleagues 
suggest that short luteal phase may be an early manifestation of 
future development of the amenorrhea-galactorrhea syndrome and, 
therefore, hyperprolactinemia should be looked for and treated if 
89 present. The relationship of hyperprolactinemia and luteal 
phase deficiencies, and the beneficial effect of bromocriptine in 
correcting the luteal phase under these circumstances was later 
90-92 
reported by others. 
IV. HYPOTHALAMIC DYSFUNCTION 
Hypothalamic amenorrhea, often implicated in women with 
secondary amenorrhea, is a catch-all diagnosis which includes 
cases with no obvious organic cause for amenorrhea, and also 
those cases where psychogenic factors may be implicated. Toll's 
and Naftolin use the following criteria to diagnose hypothalamic 
amenorrhea: (1) Normal to low basal serum gonadotropin levels; 
(2) Adequate reserves of pituitary gonadotropins; (3) No evi- 
93 dence of pituitary tumor. Two categories of hypothalamic 
(22) 

amenorrhea which have received much attention in the literature are 
psychological amenorrhea, and athlete/weight loss amenorrhea. 
Hypothalamic amenorrhea was first described by Klinefelter et 
94 
al in 1943. They showed that emotionally disturbed women with 
ovarian dysfunction had normal FSH levels but extremely low estrogen 
levels. The authors therefore hypothesized that there was failure of 
the hypothalamic-pituitary release of LH which prevented estrogen 
secretion by the ovaries. In 1944 Whitacre and Barrera reported a 
14.8% incidence of amenorrhea amongst women interned in Manila 
95 during World War II. They hypothesized that the "war amenorrhea" 
was due to psychic shock, fear, and worry and that this affected the 
autonomic nervous system which in turn led to suppression of ovarian 
funetion. 
Various authors have found evidence for different endo- 
crinologic profiles of patients in this category. For example, 
96 Rakoff divided 38 patients into six hormonal patterns. They 
noted that the most common pattern in women with both acute and 
chronic psychological dysfunction was simple hypogonadotropism, 
followed by the group with primary ovarian inhibition characterized 
by high FSH and low estrogens in the case of the acute group, and a 
persistent estrus pattern in the case of the chronic group. Matsumato 
et al studied 54 women with psychogenic or environmental 
(23) 

amenorrhea and found most of them to have low total gonadotro¬ 
pin levels, low serum LH, high 17-0H- corticosteroids, and high 
97 17-ketosteroids. They explained this by citing the "shift 
98 phenomenon" hypothesized by Seyle in 1952. This theory 
proposes that amenorrhea develops because during emergency the 
hypothalamus stimulates the pituitary to release more ACTH at the 
expense of gonadotropin. Thus, these patients have high urinary 
17-OH-corticosteroids and low gonadotropin and estrogen levels. 
Rothman et al_ reported six patients with no organic cause 
for their infertility who were treated by supportive psychothera- 
99 py for 4 to 12 months. The sessions exposed feelings of self- 
criticism on the part of the patients in that they felt that 
their infertility was a punishment for earlier wrong doings or 
bad thoughts. All six women became pregnant and had normal de¬ 
liveries following the psychotherapy. The authors suggest using 
psychotherapy as an approach to the infertile woman with no organ¬ 
ic etiology of her infertility. 
Similarly, Lachelin and Yen studied a series of 11 normo- 
gonadotropic patients with amenorrhea and apparent psychological 
disturbances.1^ These patients all had normal age of menarche 
and development of secondary sexual characteristics. Their basal 
levels of pituitary and ovarian hormones were within the range 
found in the early follicular phase of normal women. Their 
(24) 

psychological disturbances included some depression, and they 
resumed normal cyclic menstrual function following counseling. 
Based on the cure effected by counseling in these patients, the 
authors postulated that these patients have acyclicity of gonado¬ 
tropin release due to suprahypothalamic dysfunction. This might 
be related to disorders of the metabolism of central catechola¬ 
mines which are associated both with psychological depression and 
also with the regulation of hypothalamic and thus pituitary go¬ 
nadotropin secretion. The ovaries of these patients are 
sensitive to gonadotropin stimulation and undergo follicular 
activity. However, the acyclic gonadotropin release which is 
present leads to inability of the follicles to mature. 
A subdivision of the group of patients with psychological 
aspects to their infertility, are those women with anorexia ner¬ 
vosa. Anorexia nervosa is a disorder characterized by extreme 
voluntary weight loss associated with abnormal ideation regarding 
food and body image. Many endocrinological studies have been 
performed on these patients to try and elucidate the mechanism of 
their amenorrhea. Knuth et a]_ found amenorrhea due to loss of 
weight in 39 of 170 consecutive patients presenting with amen¬ 
orrhea.^ Twenty-four of these patients had anorexia nervosa; 
in the remaining 15 patients it was not clear whether their weight 
loss was due to this disorder. Endocrine studies revealed 

decreased estrogen production, low serum LH levels, and a failure 
to ovulate with the administration of clomiphene in all patients. 
Thirty-six percent of the patients resumed ovulatory menstrual 
cycles after gaining a mean of 3.6 kg. The authors concluded that 
a significant loss of weight rather than falling below an absolute 
minimum weight for height is the critical factor causing ovulatory 
dysfunction in these patients. Vigersky et al_ studied endocrine 
function in 19 patients with simple weight loss and secondary 
amenorrhea and compared the results to patients with anorexia 
102 
nervosa. They found abnormal thermoregulatory function in 
these patients which correlated with their percentage below ideal 
body weight. In addition, partial diabetes insipidus was found 
in 27% of these patients. They also had delayed peak plasma LH 
and thyrotropin levels after administration of exogenous LHRH and 
TRH, respectively. These findings were similar to those found in 
the patients with anorexia nervosa but to a lesser degree. In 
light of the abnormal thermoregulation and partial diabetes 
insipidus exhibited by these patients, hypothalamic dysfunction as 
a result of weight loss was postulated as the etiology. This may 
be due to the ability of the adipose tissue of the breast, 
abdomen, omentum, and fatty marrow of the long bones to aromatize 
androgens to estrogens.^ 
(26) 

It has been shown that there are estrogen receptors pre¬ 
sent in dopaminergic neurons of the hypothalamus. Estrogen feed¬ 
back effects may, therefore, modulate inhibition of GnRH release 
14 by dopamine. Therefore, in the presence of low circulating 
estrogen, this hypothalamic function would be modified. This 
hypothesis is consistent with the study by Wentz, whose results 
indicated that amount of body fat was more crucial in determining 
menstrual function than absolute body weight or amount of weight 
Wc 104 loss. 
There have been numerous reports in the literature concern¬ 
ing amenorrhea in athletes. In contrast to weight loss patients, 
Schwartz et a]_ found elevated LH levels in runners with amenor- 
105 
rhea. They also demonstrated that compared to runners with 
normal cycles, amenorrheic runners had a higher incidence of 
prior menstrual irregularity, weighed less, had a lower percen¬ 
tage of body fat, and were faster runners. Studies by Baker et 
al contradicted the hormonal results of Schwartz in that they 
found LH and also prolactin levels to be lower in the amenorrhe- 
106 ic group compared to normals. They found secondary amenor¬ 
rhea had the highest incidence in younger, nulliparous runners 
with late onset of menarche. Frisch and colleagues showed that 
runners and swimmers who had begun training prior to puberty had 
delayed onset of menarche and all athletes had an increased in- 
(27) 

103 
cidence of oligomenorrhea and amenorrhea with training. They 
hypothesized that a raised lean/fat ratio might explain the men¬ 
strual dysfunction in athletes since in women athletes, propor¬ 
tionally more body weight is represented by muscle rather than 
adipose tissue. They also noted that the stress of training 
might lead to increased output of adrenal corticosteroids and cat 
echolamines, which would influence the hypothalamic-pituitary con 
trol of gonadotropin secretion. As can be seen from these and 
other reports,107,108 there is not yet a consensus as to the 
mechanism involved in causing anovulatory cycles in women under¬ 
going various forms of stress. However, it is clear that hypo¬ 
thalamic dysfunction in some way may be implicated. 
Treatment of Hypothalamic Dysfunction 
All of the pharmacological compounds previously mentioned 
in reference to other disorders have been used to treat hypotha¬ 
lamic anovulation. In the clomiphene study by Garcia et a^, 75 
patients had either psychogenic, weight loss, or idiopathic 
amenorrhea or oligomenorrhea. Of these patients, 50% of the 
psychogenic amenorrhea patients, 60% of the weight loss patients, 
and 50% of the idiopathic oligomenorrhea patients ovulated with 
clomiphene. Gysler et aj_ reported a higher incidence of ovula¬ 
tion, 77%, in the patients with hypothalamic-pituitary dysfunc- 
27 tion treated with Clomid. This difference between the two 
studies may have been due to population or drug administration 
difference. 
(28) 

Human menopausal gonadotropin has also been used to treat 
hypothalamic dysfuntion. In the series published by Spadoni et 
al, 12 patients had anovulation or oligoovulation of unknown 
109 
etiology. Of these, all had ovulation successfully induced 
with HMG. 
Bromocriptine has also been shown to be effective in treat¬ 
ing this disorder. This was reported by Tolis and Naftolin in 
93 three patients and Seppala et al_ in nine of 18 normoprolactin- 
emic patients.^ The former group postulated a central action 
of the drug on catecholamine receptors as the mechanism of its 
action. More recently, Koike et al_ publ ished results of therapy 
using combination bromocriptine-clomiphene therapy in normopro- 
lactinemic patients who did not respond to clomiphene alone.^ 
Sixty-one percent of their paients became ovulatory with this 
treatment. Treatment caused a decrease in serum prolactin 
levels, and a gradual increase in serum LH levels followed by an 
LH surge. 
From the results of these studies, it may be concluded 
that clomiphene is the first line drug of choice for hypothalamic 
amenorrhea. If this fails, other drugs or drug combinations 
should be tried. In addition, psychotherapy may be helpful in 
selected patients. 
(29) 

3. METHODS 
The records of 675 patients seen at the Yale Infertility 
Clinic over a period of six years were reviewed. These patients 
represented all the patients who had presented with primary or 
secondary infertility seen by one physician (A.D.) from 1976 to 
1982, excluding those with no follow-up visits. Also excluded 
were those patients whose infertility was due to previous tubal 
ligation and those patients in whom habitual abortion was the 
principal reason for seeking medical assistance. 
The work-up of each patient in the study involved the 
currently accepted routine evaluation of the infertility patient. 
It included basal body temperature profiles, serum progesterone 
determination, and endometrial biopsy as evaluators of ovulatory 
activity or inadequate luteal phase. Each patient submitted for 
analysis a semen specimen from her partner that was judged normal 
if it had greater than 20 million sperm per high-power field, 
greater than 60% motile forms, and greater than 60% normal 
morphology. Tubal function and anatomy were assessed using hys- 
terosalpingography with water soluble or oil soluble dye as well 
as laparoscopy performed under general anesthesia. Postcoital 
cevical mucus analysis was considered normal if greater than 10 
sperm per high-power field were visualized. 
(30) 

In specific patients ancillary testing was done to further 
document the diagnosis. Patients with pituitary adenomas and 
hyperprolactinemia had visual field examinations, CAT scan, and 
thyroid function studies. Patients with hypothalamic amenorrhea 
had gonadotropin assays. Those with PCOD had total and free 
testosterone evaluations. All patients with ovulatory difficulty 
had thyroid function studies and prolactin and gonadotropin 
levels measured to rule out specific pathology. 
After analyzing the diagnoses and treatments the patients 
had received in the process of evaluation of their infertility, 
those patients whose chief diagnosis consisted of some type of 
ovulatory dysfunction were considered. If the patient never con¬ 
ceived while being treated at the infertility clinic, she was 
excluded from the study population. The study population thus 
consisted of those women with primary or secondary infertility 
due to some disorder of ovulation who had become pregnant at 
least once while being treated with an ovulation-inducing agent. 
The circumstances of their subsequent pregnancies were then 
analyzed as to whether or not medical therapy was necessary to 
conceive. Letters containing questionnaires (see Fig. 1, Appen¬ 
dix) were sent to all patients for whom follow-up was unknown, 
including those where it was not known whether even one concep¬ 
tion had occurred. Results were analyzed using the Chi-square 
test. 
(31) 

4. RESULTS 
One-hundred-thirty-two letters were sent to patients who 
were lost to follow-up from the infertility clinic. Of these, 83 
patients responded (63%), 16 letters were undeliverable, and 33 
letters were not returned; presumably these patients chose not to 
answer the questionnaire. The results from these questionnaires 
were combined with the data gleaned from patients' charts to 
yield the following results (see Fig. 2, Appendix). Of 675 pa¬ 
tients presenting to the Yale Infertility Clinic, 227 (34%) were 
found to have ovulatory dysfunction as the principal cause for 
their infertility. The remaining 449 patients had male, anatom¬ 
ical, or immunological factors as their presumed reasons for 
infertility. Of the 227 patients with the diagnosis of an ovula¬ 
tory abnormality, 102 (45%) achieved pregnancy with medical ther¬ 
apy. These 102 were then studied in detail concerning attempts 
at subsequent pregnancies. Thirty-six patients were known to be 
interested in conceiving again. Eleven of these patients (31%) 
conceived spontaneously without additional treatment (p<0.1) 
following the birth of their first child. Twenty-five patients 
were unable to achieve a second pregnancy without medication. 
Thirteen of these patients did become pregnant with medical treat¬ 
ment and 12 are in the process of being treated with ovulatory 
agents but have not yet become pregnant. Of the remaining 
(32) 

58 of the original 102 patients who conceived at least once, 
10 are in the midst of their first pregnancy, 17 are not interest 
ed in having another child at this time, and the follow-up is un¬ 
known for 31 patients, including patients who did not return the 
questionnaire and those who only partially completed the question 
naire which was sent to them. 
The 11 patients who spontaneously became pregnant compose 
a varied picture (see Fig. 3, Appendix). Their ages at presenta¬ 
tion range from 27 to 33 years old, with a mean and median age 
both equal to 30. Eight (73%) suffered from primary infertil¬ 
ity; the remaining three had been pregnant before. Six patients 
(55%) were considered to have hypothalamic oligoovulation or an¬ 
ovulation because no other explanation for their ovulatory dys¬ 
function could be determined. Five of these six patients conceiv 
ed while taking Clomid; one required Pergonal and HCG. Of the 
remaining five patients, three had polycystic ovary disease, one 
had hyperprolactinemia, and one had luteal phase deficiency. 
The distribution of the 25 patients who did not conceive 
spontaneously differed from the group that did (see Fig. 4, Appen 
dix). Their ages at presentation ranged from 24 to 37 with a 
mean and median age equal to thirty years old. The incidence of 
primary versus secondary infertility in this group was almost 
equal; 13 patients with primary, and 12 patients with secondary 
(33) 

infertility- Short luteal phase was diagnosed in 12 patients 
(48%) and hypothalamic anovulation was the diagnosis in 10 (40%). 
Three patients had PCOD, and no patients had hyperprolactinemia. 
Fifteen patients (60%) conceived the first time using Clomid, 
while the other 14 patients were divided amongst various thera¬ 
pies. 
5^ DISCUSSION 
Pregnancy was used as the endpoint in this study, rather 
than ovulation, as pregnancy is the only absolute indication of 
treatment success and consequent normal ovulation. Thirty-four 
percent of patients with infertility were found to have ovulatory 
problems as the main explanation for their infertility. This is 
a somewhat lower percentage than that reported by others. Cox 
5 
found a prevalence of 43% ovulatory failure in his population, 
while Thomas and Forrest found a 50% rate in theirs. The lower 
percentage of patients in this category found in the present 
study could be explained by the fact that the Yale Infertility 
Clinic is known for its innovative microsurgical techniques and 
therefore many patients with tubal problems are referred to Yale 
for treatment. This may result in a skewed patient population. 
The pregnancy rate in this population, 45%, was also somewhat 
(34) 

lower than previous series which vary from 56 to 93% in anovula- 
r r i 1 o 
tory populations. * * One explanation for this lower 
success rate in the present study is that of the 227 patients 
where ovulatory dysfunction was diagnosed as the major contribut¬ 
ing factor to infertility, 57 patients (25%) had other relative 
contributory problems. These included six patients who had par¬ 
tially obstructed fallopian tubes on hysterosalpingogram, three 
patients with uterine factors, seven patients whose partners had 
a sperm count in the intermediate range of 20 to 40 million/cc or 
sperm with decreased motility, eight patients with endometriosis, 
28 patients with possible cervical mucus hostility problems, and 
five patients with two of these problems in addition to ovulatory 
dysfunction. These patients were not excluded from the study 
population as none of these findings absolutely preclude fertil¬ 
ity, and, in fact, several of the patients who did conceive were 
in this category. 
There is no consistent pattern which differentiates those 
women who were able to conceive spontaneously the second time 
from those who again required medication. Their mean and median 
age at presentation was 30 years in both groups. In both groups 
hypothalamic anovulation comprised a high proportion of the pat¬ 
ients, and in the group that spontaneously conceived it was the 
diagnosis in the majority of the patients. Contrary to what one 
(35) 

might expect, there were more patients with primary infertility 
who were able to spontaneously conceive the second time, than 
with secondary infertility. 
With no obvious distinction between those patients who 
were able to conceive spontaneously and those who were not, we 
must try to explain what might possibly have enabled some 
patients to become pregnant without ovarian stimulation, where 
such stimulation had been required previously. 
This phenomenon has been previously reported by others. 
In 1972 a British study found that of 40 patients who became 
pregnant after treatment, 12 (30%) became pregnant again within 
114 two years without further treatement. A report from Austra¬ 
lia studied 100 women who had been previously treated with clomi- 
115 phene or gonadotropins for anovulatory infertility. Sixty- 
nine of these women became pregnant during this treatment. Of 
these 69 women 210 (30%) achieved a second pregnancy after spon¬ 
taneous ovulation. Also, five patients who had not previously 
achieved pregnancy with treatment, spontaneously conceived during 
the follow-up period. A group from the same institution publish- 
11 r 
ed another series of patients a year later. Of 136 patients 
who had previously withdrawn from ovulatory treatment or who had 
an induced-ovulation pregnancy, 80 (59%) exhibited improved 
menstrual patterns. Forty-six of these patients spontaneously 
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became pregnant again within one year (34%). These results are 
not directly comparable with the other studies cited because 
the population being considered differs. Another study which 
used the same population as the one just cited, i.e, women who 
had previous ovulatory stimulation either with or without concep- 
5 
tion, found a 16% spontaneous pregnancy rate. 
There are several possible explanations for the occurrence 
of spontaneous pregnancy in women where treatment was previously 
required: (1) Patients were not adequately evaluated initially 
and therapy was commenced when not indicated; (2) Ovarian stimu¬ 
lation medication has a long term effect; (3) Pregnancy induces 
long term changes in the hypothalamic-pituitary-ovarian axis; (4) 
Changes in the patient's emotional attitudes, either consciously 
or subconsciously, as a result of being pregnant or for other rea¬ 
sons influences the hypothalamic-pituitary-ovarian axis. 
It is unlikely that the first of these explanations holds 
true in this study. All patients had been infertile for at least 
one year with adequate coital activity prior to initiation of 
evaluation. Basal body temperature charts, luteal phase endome¬ 
trial biopsies, and serum progesterone measurements were used to 
compliment each other to make the correct diagnosis in each 
patient along with hormonal studies when applicable. However, it 
is possible that undocumented sporadic ovulations can lead to 
(37) 

fertilization and implantation. This is known to occur in the 
case of PCOD. In as series of 39 patients with PCOD reported by 
Goldzieher and Green, a corpus luteum was found at surgery in 
four patients, a biphasic temperature curve was seen in one pa¬ 
tient, three patients had dysmenorrhea, and five had borne chil¬ 
dren previously.^7 These findings were interpreted as evi¬ 
dence of ovulation in these patients with proven polycystic ova¬ 
ries. Similarly, in patients with hypothalamic anovulation, 
intermittent ovulation might occur. For example, a study of the 
menstrual patterns of ballet dancers showed that menstrual regu- 
108 larity improved during periods of injury and vacation. Pre¬ 
sumably the decreased level of stress at these times influenced 
the hypothalamic-pituitary axis to promote normal ovulatory func¬ 
tion. 
It is possible that the spontaneous conceptions might be 
due to a long term effect of the stimulatory medications used. 
Spontaneous pregnancy has been documented in the case of gonado¬ 
tropin therapy. Thompson and Taymor reported that of 38 anovula¬ 
tory patients who became pregnant following HMG induction of ovu¬ 
lation, eight (21%) subsequently conceived spontaneously without 
118 
additional therapy. Seven of these eight women had PCOD. 
In a more recent report, 24% of patients who had an HMG/HCG induc- 
119 
ed pregnancy, subsequently conceived spontaneously. The same 
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long term influence on ovulatory function has not been demonstrated 
as convincingly in the case of clomiphene. Garcia et al_ reported 
that of 131 patients with disorders of ovulation who did not become 
pregnant after clomiphene therapy, 23 achieved pregnancy from a 
62 
spontaneous ovulation following cessation of clomiphene therapy. 
In this case the variable of pregnancy is not present, however, it 
is not clear whether the spontaneous pregnancies were a direct 
result of the clomiphene therapy. There has been little research on 
possible long term effects of clomiphene. 
A recent in vitro study using pituitary cell cultures showed 
that the effect of bromocriptine in lowering prolactin secretion is 
120 
sustained after removal of the drug. However, this has only 
rarely been shown to be the case in vivo. In an early trial of 
bromocriptine, Del Pozo et al_ found that hyperprolactinemia and 
84 galactorrhea tended to recur when therapy was withheld. Seppala 
et al_ also reported that with most of their patients who responded 
to bromocriptine administation, the effect did not persist after the 
drug was discontinued.11*1 However, menses appeared spontaneously 
after treatment in four of their patients, and another two patients 
had "fairly" regular cycles for a year following discontinuation 
of therapy. Several studies of the effect of bromocriptine on 
pituitary prolactinomas have documented dramatic rises in prolactin 
levels11^117 and also increase in the size of tumors117 after 
discontinuation of the drug. 
(39) 

The preceeding data illustrates that except in the case of 
gonadotropin therapy, there is no indication that ovarian stimula¬ 
tory medication has long term effects. In the present study, 
seven patients who conceived spontaneously for their second preg¬ 
nancies had been treated with clomiphene, one with bromocriptine, 
one with clomiphene and bromocriptine, and only two with gonado- 
tropins. 
It is conceivable that pregnancy itself has a long term 
therapeutic effect on the hypothalamic-pituitary-ovarian axis. 
This would be difficult to prove. However, since oral contracep¬ 
tives induce a state of "pseudopregnancy", they may be used as a 
121 
model to study the effects of pregnancy. For several years 
it was believed that oral contraceptives could lead to amenorrhea 
122-124 
after they were discontinued. A hypothalamic mechanism 
was implicated to explain this. However, more recently it has 
been suggested that the syndrome of "post-pill amenorrhea" does 
not exist as such. Tolis et a]_ found no difference in historical 
or biochemical characteristics between women with secondary amen¬ 
orrhea who had discontinued oral contraceptive therapy and those 
125 
who had never taken oral contraceptives. Jacobs et al_ compar¬ 
ed patients who developed amenorrhea after discontinuing oral 
(40) 

contraceptive therapy with other patients with secondary amenor- 
1 
rhea. The two groups of patients had similar characteris¬ 
tics; both groups had similar percentages of patients with pri¬ 
mary ovarian failure, hyperprolactinemia, recent weight loss, and 
psychological disorders to explain their amenorrhea. In addition, 
almost half of the post-oral contraceptive amenorrhea patients 
had had episodes of amenorrhea previously. The authors concluded 
from this data that oral contraceptive use does not cause subse¬ 
quent amenorrhea. Friedman and Goldfien also found that there was 
no significant difference between patients with post-oral contra¬ 
ceptive amenorrhea and other patients with secondary amenor- 
127 
rhea. Halbert and Christian reported a high incidence of 
128 prior menstrual dysfunction in these women. The latter two 
groups also noted a high incidence of galactorrhea amongst post¬ 
pill amenorrheic patients; nine of 21 patients presented by Fried- 
127 
man and Goldfien, and 10 of 35 patients of Halbert and Chris- 
128 tian. Although the explanation for this finding is not 
known, it is possible that the symptoms of a developing pituitary 
adenoma are masked during oral contraceptive therapy, only becom¬ 
ing apparent when the hormonal therapy is discontinued. A simi¬ 
lar mechanism might be involved in the so-called Chiari-Frommel 
syndrome, or postpartum amenorrhea-galactorrhea. 

The preceeding discussion illustrates that the current evi 
dence does not support the idea that exogenous hormonal therapy, 
and by inference, the similar hormonal milieau present during 
pregnancy, has direct effects on the hypothalamic-pituitary axis. 
Lastly, changes in a woman's emotional or mental status 
might cause a change in ovulatory patterns via central mechan¬ 
isms. This association has been noted by numerous authors (see 
p. 22-29), however it is difficult to prove as the elucidation of 
central neuroendocrine pathways which interrelate thought and 
emotion with reproductive physiology is only in its infancy. 
The study presented in this paper was retrospective in de¬ 
sign. Ideally, a random double-blind study would yield the most 
unbiased analysis of this patient population. While the with¬ 
holding of treatment in this case would not be life-threatening, 
due to the sensitive nature of the disorders involved and the fin 
ite time period of reproductive life, it would not be ethical to 
withhold treatment from any patient where it might be potential¬ 
ly beneficial. In this study a significant number of women with 
diagnosed ovulatory dysfunction were able to conceive spontaneous 
ly after a successfully induced pregnancy. The 31% success rate 
114 115 
agreed with that found in previous studies. * The patho¬ 
physiologic mechanism which might explain this finding is not 
known, however, it most likely involves either intermittent 
(42) 

spontaneous ovulations found in certain anovulatory syndromes, or 
psychologic or emotional changes influencing the hypothalamic- 
pituitary system via suprahypothalamic pathways. There is little 
evidence supporting a long term effect on the hypothalamic-pitui¬ 
tary-ovarian axis by either medications or pregnancy. 
(43) 

APPENDIX 
(44) 

Figure l 
Yale University 
QUESTIONNAIRE 
SCHOOL OF MEDICINE 
33 3 Cedar Street 
P.0. Box 3333 
New Haven. Connecticut 06510 
Department oj Obstetrics and Gynecology 
Dear Ms. 
We are doing a study designed to help answer the question of whether 
certain drugs are effective in helping women with problems of ovulation 
to conceive, and whether these drugs are necessary each time conception is 
desired. As a present or past patient of the Yale Infertility Clinic, we 
would appreciate it if you would take a few minutes to answer the follow¬ 
ing questions. Not all of these questions may be applicable to you. In 
some cases we may already have this information in your clinic file, but 
please answer whichever questions you think apply to you anyway. Answers 
to these questions will be strictly confidential, and will not become a 
part of your permanent clinic or hospital files. 
1. Were you found to have problems with ovulation: e.g. abnormal basal 
body temperature charts, short luteal phase, polycystic ovaries, etc., 
during evaluation for infertility? 
Yes___ No_ 
Specify diagnosis:___ 
2. Did you take any medications, either prescribed by the Yale Infertility Clinic 
or subsequent physicians you may have seen, for this problem? 
Yes No_ 
Specify which: 
Clomid_ HCG_ 
Cortisone_ Pergonal_ 
Progesterone Suppositories_ Parlodel_ 
Other (e.g. Surgery)____ ________ 
Combination of 

FIGURE 1 (Continued) 
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3. Did you become pregnant as a result of taking this medication? 
Yes__ No_ 
If yes, which of the listed medications were you taking when you conceived, 
if any? 
4. If you became pregnant, what was the outcome of that pregnancy? 
Full term delivery_ 
Premature delivery_ 
Miscarriage (at how many weeks?_)_ 
Ectopic (tubal) pregnancy_ 
Abortion_ 
Other  
5. If you are no longer a patient at the Yale Infertility Clinic, whether or 
not you became pregnant while under their care, please summarize below your 
attempts at having a child since that time. 
a) Saw or currently seeing another physician who treated me with_ 
and I did, did not, become pregnant. 
b) Adopted a child and I am, am not, still actively pursuing a pregnancy. 
c) Still have no children and I am, am not, actively pursuing pregnancy 
and/or adoption. 
d) Have decided that I am no longer interested in having a child because 
e) Other 
6. In the space below, please add any other comments you think may be helpful 
for this study. 
(46) 
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